| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 1.5 | 0.3 | 0.3 |
| Other income | 0.2 | 0.0 | 0.0 |
| Total income | 1.7 | 0.3 | 0.4 |
| Profit before exceptional items & tax | 1.9 | -1.9 | -1.4 |
| Profit before tax | 1.9 | -1.9 | -1.4 |
| Net profit | 1.9 | -1.8 | -1.4 |
| Operating margin | 111.8% | -633.3% | -350.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +400.00% |
|---|
BSE results filing, NSE: VANTA. Figures extracted from the filing.
Vanta Bioscience Ltd: key numbers
- Share price
- ₹20.42
- Market cap
- ₹14.52 Cr
- Revenue (annual)
- ₹1.82 Cr
- Net profit (annual)
- ₹0.11 Cr
- P/E (TTM)
- 134.1×Sector 34.2×
- Promoter holding
- 72.81%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vanta Bioscience Ltd
All →Vanta Bioscience Annual General Meeting
Vanta Bioscience Ltd has issued notice for its upcoming Annual General Meeting scheduled for September 30, 2026, to transact key business resolutions.
Vanta Bioscience Annual Report
Vanta Bioscience Ltd submitted its Annual Report and AGM notice for FY 2025-26. The 10th AGM is scheduled for September 30, 2026.
Vanta Bioscience Annual General Meeting
Vanta Bioscience approved the Annual Report for FY 2025-26 and scheduled the 10th Annual General Meeting for September 30, 2026.
Vanta Bioscience Financial Results
Vanta Bioscience Limited approved audited standalone and consolidated financial results for FY2026. The board also re-appointed Mr. Dopesh Raja Mulakala as Managing Director for three years.
Vanta Bioscience Board Meeting Date
Vanta Bioscience scheduled a board meeting on May 30, 2026, to approve fiscal 2026 financial results. The trading window remains closed until June 1, 2026.